Skip to main
HCA

HCA Healthcare (HCA) Stock Forecast & Price Target

HCA Healthcare (HCA) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 41%
Hold 24%
Sell 6%
Strong Sell 0%

Bulls say

HCA Healthcare has demonstrated notable financial growth, highlighted by a 9.2% increase in same-facility revenues and a 7.1% rise in inpatient revenue per admission year-over-year during the third quarter of 2025. Additionally, the organization's strong payer mix has enabled significant revenue growth across various segments, with Medicare and commercial admissions seeing year-over-year increases of 3.4% and 3.7%, respectively. Furthermore, HCA raised its 2025 adjusted EBITDA guidance to a range of $15.25 billion to $15.65 billion, reflecting core operational strength and a positive shift in the revenue outlook.

Bears say

HCA Healthcare's total debt to last twelve months (LTM) EBITDA ratio decreased slightly to 2.9x in the third quarter of 2025, indicating a potential concern regarding future earnings growth amidst a forecasted headwind for 2026. Additionally, the company has revised its estimated EBITDA growth down to 3.9%, which falls below the low end of its long-term growth outlook, suggesting weakening operational performance. The adjustment of HCA's leverage target to a narrower range of 2.75x-3.75x further highlights increasing caution about the company's financial stability in the changing economic environment.

HCA Healthcare (HCA) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 41% recommend Buy, 24% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HCA Healthcare (HCA) Forecast

Analysts have given HCA Healthcare (HCA) a Buy based on their latest research and market trends.

According to 17 analysts, HCA Healthcare (HCA) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $475.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $475.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HCA Healthcare (HCA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.